I remind you that Acadia, in addition to the earnings at the end of February, is awaiting the data from the phase 3 study on negative symptoms in schizophrenia (fundamental for the future of Nuplazid) expected by March 31st, news can come out every day:
The Company expects to report top-line results from ADVANCE-2, a Phase 3 study evaluating pimavanserin for the treatment of the negative symptoms of schizophrenia in the first quarter of 2024
Acadia, page-110
-
- There are more pages in this discussion • 816 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.32 |
Change
-0.020(0.16%) |
Mkt cap ! $1.572B | |||
| Open | High | Low | Value | Volume |
| $12.30 | $12.40 | $12.16 | $1.204M | 97.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 219 | $12.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1270 | 18 |
View Market Depth
| Last trade - 15.53pm 05/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |